

Summer Training Institute for Randomized Clinical Trials Involving Behavioral Interventions

Tab 6 Course Bibliography

An asterisk (*) indicates a *Required Reading*. Reprints of *Required Reading* are located behind the tab in this binder for the associated lecture. When available, reprints of *Suggested Readings* are located immediately following this bibliography in alphabetical order of the author's last name. **Bold** type indicates a copy of the *Suggested Reading* article is reprinted here.

Beecher, H. K., The powerful placebo. *JAMA*¹, 1955, 27, 1602-1606.

*The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research, April 18, 1979 (Department of Health, Education, and Welfare)

Buyse, M. E., Analysis of clinical trial outcomes: Some comments on subgroup analyses, *Control Clin. Trials*, 1989, 10 : 187s-194s.

*Code of Federal Regulations, Title 45, Part 46, Subpart A, Protection of Human Subjects.

*Friedman LM, Furberg CD, and DeMets DL, *Fundamentals of Clinical Trials, Third Edition*. New York: Springer-Verlag, 1998, selected chapters.

Furberg, C. D., et al., Subgroup interaction in the Heart and Estrogen/Progestin Replacement Study: Lessons learned. *Circulation*, 2002, 105: 917-922.

Geller, N. L., and M. Proschan, Meta-analysis of clinical trials: A consumer's guide, *Journal of Biopharmaceutical Statistics*, 1996, 6 (4), 377-394.

*Glasgow, RE, Vogt, TM, & Boles, SM, Evaluating the public health impact of health promotion interventions: The RE-AIM framework, *Am J Pub Health*, 1999, 89(9): 1322-1326.

*Goldman, Lee, Phillips, K.A., Coxson, P., Goldman, P.A., Williams, L., Hunink, M., Weinstein, M.C., The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost, *Journal of the American College of Cardiology*, 2001, 38(4): 1012-1017.

*Hrobjartson, A. & P. C. Gotzsche, Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *New England Journal of Medicine*, 2001, 244, 1594-1602.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA*. 1998 Aug 19; 280 (7): 605-13

*Kaplan, RM, Quality of Life and Chronic Illness, in A.Christensen and M. Antoni (eds.), *Chronic Physical Disorders: Behavioral Medicine's Perspective*. Blackwell Publishing, 2002

*Kaplan RM and Groessl EJ, Application of cost-effectiveness analysis in behavioral medicine, *Journal of Consulting and Clinical Psychology*, 2002, 70(3): 482-493.

Lavori P.W., Clinical trials in psychiatry: should protocol deviation censor patient data? *Neuropsychopharmacology*, 1992, 6:39-47

Lavori, P. W., Dawson R. Designing for intent-to-treat. *Drug Info J*, 2001, 35:1079-1086.

*Lichstein, K. L., Riedel, B. W., & Grieve, R. (1994). Fair test of clinical trials: A treatment implementation model. *Advanced Behavioral Research Therapy*, 1994, 16, 1-29.

¹ Journal of the American Medical Association

Summer Training Institute for Randomized Clinical Trials
Involving Behavioral Interventions

*Meinert C. L. *Clinical Trials: Design, Conduct and Analysis*. New York, New York: Oxford University Press, 1986, Chapter 14, pp. 149-158.

Miklowitz, D. J., Clarkin, J.F. Balancing internal and external validity. *Prevention & Treatment*, 1999, 2, (<http://www.journals.apa.org/prevention/volume2/toc-mar21-99.html>)

Moncher, F. J. & Prinz, R. J. Treatment fidelity in outcome studies. *Clinical Psychology Review*, 1991, 11, 247-266.

Oxman, A. D., and Guyatt, G. H., A consumer's guide to subgroup analyses, *Ann. Intern. Med.*, 1992, 116(1): 78-84.

*National Institutes of Health Policy and Guidelines for the Inclusion of Children as Participants in Research Involving Human Subjects, March 6, 1998.

*National Institutes of Health Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, March 18, 1994.

Persons J.B. and Silberschatz G., Are results of randomized controlled trials useful to psychotherapists? *Journal of Consulting and Clinical Psychology*, 1998, 66(1): 126-135.

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. *N Engl J Med.* 1989 Aug 10; 321(6): 406-12

*Rosa, Linda, *et al.*, A close look at therapeutic touch. *JAMA*, April 1, 1998, 279 (13), pp. 1005-1010, and Letters to the Editor, *JAMA*, December 9, 1998, 280 (22), 1905-1908

Scientific Advisory Committee of the Medical Outcome Trust, Assessing health status and quality-of-life instruments: Attributes and review criteria, *Quality of Life Research*, 2002, 11: 193-205.

Thomson SG, Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. *Stat Methods Med Res.* 1993; 2(2): 173-92

*Turner, J. A., *et al.*, The importance of placebo effects in pain treatment and research. *JAMA*, 1994, 271, 1609-1614.

*Yusuf, S., Wittes, J., Probstfield, J., Tyroler, H. A., Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials, *JAMA*, 1991, 266 (1), 93-99.

*Wittes, J., Data safety monitoring boards: A brief introduction. *Biopharmaceutical Reports*, 2000, 8(1): 1-11.

Wittes, J., Sample size calculations for randomized controlled trials, *Epidemiologic Reviews*, 2002: 24(1), 39-53.